vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
Company profile
Ticker
VIR
Exchange
Website
CEO
George A. Scangos
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Agenovir Corporation • Encentrio Therapeutics, Inc. • Encentrio Therapeutics International GmbH • Humabs BioMed SA • TomegaVax, Inc. • Vir AU Biotechnology Pty Ltd. • Vir Biotechnology International GmbH • Vir Predictive Medicine, Inc. • VirAb, Inc. ...
IRS number
812730369
VIR stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
19 Apr 24
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
8-K
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy
18 Apr 24
S-8
Registration of securities for employees
26 Feb 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24
8-K
Departure of Directors or Certain Officers
20 Feb 24
8-K
Cost Associated with Exit or Disposal Activities
13 Dec 23
8-K
Entry into a Material Definitive Agreement
3 Nov 23
Latest ownership filings
4
Backer Marianne De
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
4
ANN M. HANLY
2 Apr 24
4
Sung Lee
28 Mar 24
4
ANN M. HANLY
26 Feb 24
4
Backer Marianne De
26 Feb 24
4
Sung Lee
26 Feb 24
4
Phillip Pang
26 Feb 24
4
GEORGE A SCANGOS
26 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 472.35 mm | 472.35 mm | 472.35 mm | 472.35 mm | 472.35 mm | 472.35 mm |
Cash burn (monthly) | 71.50 mm | 42.63 mm | 62.24 mm | 58.08 mm | 51.94 mm | 52.98 mm |
Cash used (since last report) | 490.23 mm | 292.31 mm | 426.75 mm | 398.18 mm | 356.13 mm | 363.22 mm |
Cash remaining | -17.88 mm | 180.04 mm | 45.60 mm | 74.17 mm | 116.22 mm | 109.13 mm |
Runway (months of cash) | -0.3 | 4.2 | 0.7 | 1.3 | 2.2 | 2.1 |
Institutional ownership, Q3 2023
94.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 211 |
Opened positions | 41 |
Closed positions | 54 |
Increased positions | 95 |
Reduced positions | 49 |
13F shares | Current |
---|---|
Total value | 808.05 bn |
Total shares | 126.95 mm |
Total puts | 53.30 k |
Total calls | 91.30 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Softbank Vision Fund | 20.26 mm | $0.00 |
SB Investment Advisers | 16.68 mm | $156.33 bn |
BLK Blackrock | 15.80 mm | $148.08 bn |
ARCH Venture Fund IX | 12.92 mm | $369.42 mm |
Vanguard | 11.20 mm | $104.95 bn |
STT State Street | 7.17 mm | $67.22 bn |
GSK GSK | 6.63 mm | $199.31 mm |
Baillie Gifford & Co | 3.97 mm | $37.21 bn |
Alliancebernstein | 2.90 mm | $27.15 bn |
Geode Capital Management | 1.79 mm | $16.81 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Apr 24 | Backer Marianne De | Common Stock | Sell | Dispose S | No | No | 9.4577 | 72,995 | 690.36 k | 678,457 |
1 Apr 24 | Ann M. Hanly | Common Stock | Sell | Dispose S | No | No | 10.052 | 2,711 | 27.25 k | 132,069 |
27 Mar 24 | Sung Lee | Common Stock | Sell | Dispose S | No | No | 9.8875 | 6,008 | 59.40 k | 100,492 |
22 Feb 24 | Sung Lee | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 106,500 |
22 Feb 24 | Sung Lee | Stock Option Common Stock | Grant | Acquire A | No | No | 10.11 | 80,000 | 808.80 k | 80,000 |
22 Feb 24 | Pang Phillip | Common Stock | Sell | Dispose S | No | No | 10.0456 | 14,568 | 146.34 k | 250,111 |
News
On April 15, 2024, Sung Lee, Executive Vice President And Chief Financial Officer Of Vir Biotechnology Informed The Company That He Will Be Stepping Down From His Role, Effective May 3, 2024, To Pursue Another Career Opportunity; Co Has Initiated A Search For His Successor
18 Apr 24
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
15 Mar 24
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
15 Mar 24
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
23 Feb 24
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
23 Feb 24
Press releases
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
11 Apr 24
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
22 Mar 24
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
5 Mar 24
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
23 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24